Director & Neurodegenerative Diseases Therapeutic Area Leader, Samumed
For his work in the development of SM07883, a novel small-molecule showing promise as an Alzheimer’s treatment by inhibiting Tau overexpression, reducing Amyloid buildup and inflammation.
Ben Melchior is a neuroscientist by training and is the scientific lead of the Alzheimer’s disease program at Samumed. Dr. Melchior has previously worked on government-funded research programs related to various neurodegenerative disorders including Parkinson’s disease, Multiple sclerosis, and Alzheimer’s disease. Dr. Melchior was awarded fellowship grants from both the Alzheimer’s Association and the National Multiple Sclerosis Society while a postdoctoral fellow at the Scripps Research Institute. Dr. Melchior holds a PhD in neuroimmunology from the University of Nantes, France.
Photos from the 2019 Cure Coin Award Ceremony - July 2019 - The Association, LA